PharmcoRx Pharmacy Launches Mark Cuban Cost Plus Drug Program Expanding Its In-Pharmacy Offerings
MIAMI, Nov. 27, 2023 /PRNewswire/ — PharmcoRx Pharmacy, a wholly-owned subsidiary of Progressive Care Inc (OTCQB:RXMD), today announced its expansion of in-pharmacy offerings through an agreement with the Mark Cuban Cost Plus Drug Company (“Cost Plus Drugs”). The Cost Plus Drugs program allows participating patients the ability to purchase generic and branded medicines at their cost plus a low fixed markup.
Related news for (RXMD)
- NextPlat Reports 474% Increase in Consolidated Q2 Revenues to $17 Million and Record 34.2% Quarterly Margins; $70 Million in 2024 Annual Revenues Expected
- Progressive Care Inc. Announces Second Quarter 2024 Revenues of $13.5 Million, an Increase of 17% as Gross Margin Expands to 35%
- NextPlat Expands E-Commerce Program in China to Include Broad Retail Distribution and Adds Digital/Social Media Marketing Capabilities with New Marketing Partner
- Progressive Care Inc. Announces Record First Quarter 2024 Revenues of $14.6 Million, an Increase of 28% Over First Quarter 2023 Results
- NextPlat Reports Record Consolidated Q1 2024 Revenues of $17.5 Million Compared to $2.9 Million in Q1 2023 (508% Increase) as Quarterly Margins Improve to 27.5%